Inflammation and Venous Thromboembolism in Hospitalized Patients with COVID-19.
C-reactive protein
COVID-19
inflammatory indices
interleukin-6
lymphocytopenia
neutrophil-to-lymphocyte ratio
triglyceride–glucose index
venous thromboembolism
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
19 Nov 2023
19 Nov 2023
Historique:
received:
28
08
2023
revised:
04
11
2023
accepted:
17
11
2023
medline:
24
11
2023
pubmed:
24
11
2023
entrez:
24
11
2023
Statut:
epublish
Résumé
A link between inflammation and venous thromboembolism (VTE) in COVID-19 disease has been suggested pathophysiologically and clinically. The aim of this study was to investigate the association between inflammation and disease outcomes in adult hospitalized COVID-19 patients with VTE. This was a retrospective observational study, including quantitative and qualitative data collected from COVID-19 patients hospitalized at the Infectious Diseases Unit (IDU) of the University Hospital of Ioannina, from 1 March 2020 to 31 May 2022. Venous thromboembolism was defined as a diagnosis of pulmonary embolism (PE) and/or vascular tree-in-bud in the lungs. The burden of disease, assessed by computed tomography of the lungs (CTBoD), was quantified as the percentage (%) of the affected lung parenchyma. The study outcomes were defined as death, intubation, and length of hospital stay (LoS). A chi-squared test and univariate logistic regression analyses were performed in IBM SPSS 28.0. After propensity score matching, the final study cohort included 532 patients. VTE was found in 11.2% of the total population. In patients with VTE, we found that lymphocytopenia and a high neutrophil/lymphocyte ratio were associated with an increased risk of intubation and death, respectively. Similarly, CTBoD > 50% was associated with a higher risk of intubation and death in this group of patients. The triglyceride-glucose (TyG) index was also linked to worse outcomes. Inflammatory indices were associated with VTE. Lymphocytopenia and an increased neutrophil-to-lymphocyte ratio negatively impacted the disease's prognosis and outcomes. Whether these indices unfavorably affect outcomes in COVID-19-associated VTE must be further evaluated.
Sections du résumé
BACKGROUND
BACKGROUND
A link between inflammation and venous thromboembolism (VTE) in COVID-19 disease has been suggested pathophysiologically and clinically. The aim of this study was to investigate the association between inflammation and disease outcomes in adult hospitalized COVID-19 patients with VTE.
METHODS
METHODS
This was a retrospective observational study, including quantitative and qualitative data collected from COVID-19 patients hospitalized at the Infectious Diseases Unit (IDU) of the University Hospital of Ioannina, from 1 March 2020 to 31 May 2022. Venous thromboembolism was defined as a diagnosis of pulmonary embolism (PE) and/or vascular tree-in-bud in the lungs. The burden of disease, assessed by computed tomography of the lungs (CTBoD), was quantified as the percentage (%) of the affected lung parenchyma. The study outcomes were defined as death, intubation, and length of hospital stay (LoS). A chi-squared test and univariate logistic regression analyses were performed in IBM SPSS 28.0.
RESULTS
RESULTS
After propensity score matching, the final study cohort included 532 patients. VTE was found in 11.2% of the total population. In patients with VTE, we found that lymphocytopenia and a high neutrophil/lymphocyte ratio were associated with an increased risk of intubation and death, respectively. Similarly, CTBoD > 50% was associated with a higher risk of intubation and death in this group of patients. The triglyceride-glucose (TyG) index was also linked to worse outcomes.
CONCLUSIONS
CONCLUSIONS
Inflammatory indices were associated with VTE. Lymphocytopenia and an increased neutrophil-to-lymphocyte ratio negatively impacted the disease's prognosis and outcomes. Whether these indices unfavorably affect outcomes in COVID-19-associated VTE must be further evaluated.
Identifiants
pubmed: 37998613
pii: diagnostics13223477
doi: 10.3390/diagnostics13223477
pmc: PMC10670045
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Radiology. 2020 Apr;295(1):202-207
pubmed: 32017661
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Thromb Res. 2022 May;213:138-144
pubmed: 35366435
Int J Mol Sci. 2021 May 20;22(10):
pubmed: 34065210
EBioMedicine. 2021 May;67:103378
pubmed: 34000622
Epidemiol Infect. 2021 Jan 29;149:e40
pubmed: 33509306
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Immunity. 2019 Jun 18;50(6):1401-1411.e4
pubmed: 31076358
Res Pract Thromb Haemost. 2022 Feb 15;6(2):e12666
pubmed: 35224417
Thorax. 2021 Apr;76(4):412-420
pubmed: 33408195
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Lancet Microbe. 2021 Feb;2(2):e49-e50
pubmed: 33655230
Lancet. 2022 Jan 8;399(10320):118-119
pubmed: 34800425
Nat Rev Immunol. 2021 May;21(5):319-329
pubmed: 33824483
Intell Based Med. 2021;5:100035
pubmed: 34075366
Age Ageing. 2021 Feb 26;50(2):284-293
pubmed: 33201226
JAMA. 2020 Sep 3;:
pubmed: 32880615
Int J Gen Med. 2022 Jan 31;15:985-996
pubmed: 35136352
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Am J Respir Crit Care Med. 2020 Sep 1;202(5):642-644
pubmed: 32687386
Blood Adv. 2020 Nov 10;4(21):5373-5377
pubmed: 33137202
BMC Med Inform Decis Mak. 2023 Jul 21;23(1):129
pubmed: 37479990
Crit Care Med. 2020 Sep;48(9):1358-1364
pubmed: 32467443
J Thromb Haemost. 2021 Apr;19(4):1038-1048
pubmed: 33534149
BMC Infect Dis. 2022 May 13;22(1):462
pubmed: 35562677
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
BMJ Open. 2022 Jul 1;12(7):e056685
pubmed: 35777884
Crit Care. 2020 Jun 2;24(1):275
pubmed: 32487122
Lab Med. 2021 Jan 4;52(1):10-15
pubmed: 32929506
Gut. 2020 Jun;69(6):1002-1009
pubmed: 32213556
Mod Pathol. 2021 Mar;34(3):522-531
pubmed: 33067522
Open Heart. 2020 Jun;7(1):
pubmed: 32532805
J Pers Med. 2021 Dec 08;11(12):
pubmed: 34945800
Am J Emerg Med. 2021 Aug;46:16-19
pubmed: 33706251
Chin Med J (Engl). 2020 May 5;133(9):1015-1024
pubmed: 32004165
Blood. 2020 Jun 4;135(23):2033-2040
pubmed: 32339221
J Thromb Haemost. 2021 Dec;19(12):3139-3153
pubmed: 34538015
J Med Virol. 2021 Jan;93(1):250-256
pubmed: 32592501
J Thromb Thrombolysis. 2021 Feb;51(2):446-453
pubmed: 33151461
Int J Lab Hematol. 2020 Dec;42(6):761-765
pubmed: 32779838
Cardiovasc Diabetol. 2020 May 11;19(1):58
pubmed: 32393351
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
Thromb Res. 2020 Dec;196:27-30
pubmed: 32823173
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Chest. 2021 Oct;160(4):1471-1480
pubmed: 34153340
J Med Internet Res. 2020 Nov 11;22(11):e23128
pubmed: 33035175
AJR Am J Roentgenol. 2002 Oct;179(4):897-9
pubmed: 12239033
New Microbes New Infect. 2020 Sep;37:100738
pubmed: 32834902
Front Med (Lausanne). 2021 Apr 01;8:645651
pubmed: 33869253
Sensors (Basel). 2023 Apr 22;23(9):
pubmed: 37177382
Vasc Med. 2021 Aug;26(4):415-425
pubmed: 33818197
Bone Marrow Transplant. 2021 Mar;56(3):570-580
pubmed: 32943758
Pak J Med Sci. 2021 Sep-Oct;37(5):1435-1439
pubmed: 34475926
Sci Rep. 2021 Mar 30;11(1):7166
pubmed: 33785852
Thorax. 2021 Oct;76(10):970-979
pubmed: 33622981
Chest. 2021 Mar;159(3):1182-1196
pubmed: 33217420
Inform Med Unlocked. 2023;37:101188
pubmed: 36742350
Life (Basel). 2022 Jan 25;12(2):
pubmed: 35207458
Circulation. 2020 Jul 14;142(2):184-186
pubmed: 32330083
J Infect Public Health. 2021 Nov;14(11):1708-1714
pubmed: 34700289
J Clin Lab Anal. 2022 Mar;36(3):e24216
pubmed: 35076953
Nat Rev Cardiol. 2020 May;17(5):259-260
pubmed: 32139904
Sci Adv. 2020 Aug 14;6(33):eaba3546
pubmed: 32851163
Res Pract Thromb Haemost. 2022 May 02;6(3):e12709
pubmed: 35509326
Clin Chim Acta. 2021 Jun;517:66-73
pubmed: 33639119